Physician profile
Zeming Deng
NPI 1659363463
$12,963.67
in general payments reported to CMS, 2019-2025
44 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,779 · 2020: $896 · 2021: $2,201 · 2022: $2,124 · 2023: $2,015 · 2024: $2,034 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,944 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,943.52 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,763.79 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,717.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,647.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,388.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,215.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,057.30 | 2019-2025 | |
| Amgen INC. | $617.84 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $533.46 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.91 | 2019-2025 | Jardiance, Tradjenta |
| Merck Sharp & Dohme LLC | $355.05 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Antares Pharma, INC. | $272.71 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Exact Sciences Corporation | $268.76 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $242.07 | 2022-2025 | |
| Allergan, INC. | $199.47 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $132.65 | 2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeming Deng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.